Infinity Pharmaceuticals Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998, it changed its name to Discovery Partners International, Inc., or DPI. In July 2000, it reincorporated in Delaware. On September 12, 2006, DPI completed a merger with the Company, pursuant to which a wholly-owned subsidiary of DPI merged with and into the Company. In addition, it changed its corporate name from Discovery Partners International, Inc. to Infinity Pharmaceuticals, Inc. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to patients with difficult-to-treat diseases. Its product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which is being evaluated for the treatment of hematologic malignancies, or blood cancers. The Company's product candidates, duvelisib and IPI-549 include DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Advanced Hematologic Malignancies consists of Duvelisib + Venetoclax, IPI-549: PI3K Gamma-Selective Inhibitor. As part of the DUETTS program in lymphoma, it is conducting DYNAMO, a Phase 2, open-label, single-arm monotherapy study evaluating the safety and efficacy of duvelisib dosed at 25 mg twice daily in 129 patients with iNHL. The FDA has granted orphan drug designation to duvelisib for the potential treatment of follicular lymphoma, and has granted fast track designation to the investigation of duvelisib for the treatment of patients with follicular lymphoma who have received at least two prior therapies. The Company has eight issued or allowed U.S. patents related to its duvelisib program, which expire on various dates between 2029 and 2032, excluding any patent term extension. It has three issued or allowed U.S. patents related to its PI3K gamma program, which expire on various dates between 2033 and 2034, excluding any patent term extension. In addition, it has approximately 275 patents and patent applications pending related to its PI3K programs.